Parental age and retinoblastoma—a retrospective study of demographic data and genetic analysis

EYE(2021)

Cited 1|Views8
No score
Abstract
Learning Objectives Upon completion of this activity, participants will be able to: Assess the proportion of sporadic vs heritable retinoblastoma and the association between parental age gap and risk for retinoblastoma development in offspring, based on a retrospective study in India. Evaluate the associations between maternal age and paternal age with risk for retinoblastoma development in offspring, based on a retrospective study in India. Determine the clinical implications of the associations between parental age gap, maternal age, and paternal age and risk for retinoblastoma development in offspring, based on a retrospective study in India Continuing Medical Education In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Springer Nature. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at www.medscape.org/journal/eye ; (4) view/print certificate. Credit hours 1.0 Release date: Expiration date: Post-test link: https://medscape.org/eye/posttest957229 Authors/Editor disclosure information Sobha Sivaprasad, MD, has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Allergan, Inc.; Apellis; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Heidelberg Pharma GmbH; Novartis Pharmaceuticals Corporation; Oculis; Optos; Oxurion; Roche. Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Bayer AG; Novartis Pharmaceuticals Corporation; Optos. Received grants for clinical research from: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Optos. Meghana Tanwar, DNB, FRCS, has disclosed no relevant financial relationships. Sekaran Balaji, BSc, MSc, has disclosed no relevant financial relationships. Ayyasamy Vanniarajan, MSc, PhD, has disclosed no relevant financial relationships. Usha Kim, DO, DNB, has disclosed no relevant financial relationships. Gunja Chowdhury, DO, DNB, has disclosed no relevant financial relationships. Journal CME author disclosure information Laurie Barclay, MD, has disclosed no relevant financial relationships.
More
Translated text
Key words
Mutation,Risk factors,Medicine/Public Health,general,Ophthalmology,Laboratory Medicine,Surgery,Surgical Oncology,Pharmaceutical Sciences/Technology
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined